UiPath's recent Peak acquisition is likely to drive renewed growth opportunity. Read why we are reiterating our Buy rating ...

Morgan Stanley analyst Sanjit Singh maintained a Hold rating on UiPath (PATH – Research Report) today and set a price target of $12.00.Stay ...

Visa also continually rolls out new products that deliver benefits to customers, vendors, and merchants. Earlier in April, ...

UiPath (PATH) closed the most recent trading day at $10.71, moving -1.47% from the previous trading session. The stock's performance was behind the S&P 500's daily gain of 0.79%. Elsewhere, the Dow ...

Cathie Wood's Ark Invest sold shares in UiPath, Prime Medicine, and Repare Therapeutics, with notable gains and losses.

Learn more about whether CleanSpark, Inc. or UiPath Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

UiPath (NYSE:PATH) recently launched its AI-based Medical Record Summarization Agent at the Google Cloud Next 2025 event, emphasizing efficiency and cost savings in healthcare. Despite these promising ...

UiPath shares rise on launch of generative AI-based UiPath Medical Record Summarization agent at Google Cloud Next 2025.

Detailed price information for Camping World Holdings Inc (CWH-N) from The Globe and Mail including charting and trades.

Zacks.com users have recently been watching UiPath (PATH) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Countless companies stand to benefit from AI, but these stocks have AI and automation as a central part of their businesses.